New Product: MSD has launched JANUMET® which is an addition to the recent introduction of JANUVIA®. The two fall into the same portfolio of new oral antidiabetic agent for the treatment of type 2 diabetes.

JANUVIA® contains sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor (incretin enhancer) that increases the levels of two incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones play a major physiological role in maintaining glucose homeostasis. JANUMET® is a combination sitagliptin and metformin hydrochloride, a member of the biguanide class.

Should you have any further queries please contact their Sarojini Moodley: Email: sarojini_moodley@merck.com